Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?

Abstract

Get full access to this article

View all access options for this article.

References

Rothenberg R. , Lentzner HR , Parker RA Population aging patterns: The expansion of mortality. J Gerontol 46:566-579, 1991.

Keller BK , Potter JF Predictors of mortality in outpatient geriatric evaluation and management clinic patients. J Gerontol 49:7246-7251, 1994.

McGinnis JM , Foege WH Actual causes of death in the United States. JAMA 270: 2207-2221, 1993.

Woo B. , Woo B. , Cook EF , et al. Screening procedures in the asymptomatic adult: Comparison of physicians recommendations, patients' desires, published guidelines and actual practice. JAMA 254:1480-1484, 1985 .

Scutchfield FD , Hartman KT Physicians and preventive medicine . JAMA 273: 1150-1151, 1995 .

Leutewyler C. The price of prevention. Sci Am April:124-129, 1995.

National Center for Health Statistics. Advance Report of Final Mortality Statistics, 1990. Hyattsville, Md.: U.S. Department of Health and Human Services, 1993 Monthly Vital Statistics Report 41(7), 1993 .

U.S. Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, D.C.: U.S. Department of Health and Human Services, Publications PHS 91-92, 1991.

McGinnis JM , Lee PL Healthy People 2000 at mid decade. JAMA 273:1123-1129, 1995.

10.

Lasker RD , Lee PL Improving health through health system reform. JAMA 272: 1297-1298, 1994.

11.

Scitovsky AA Medical care in the last twelve months of life: The relation between age, functional status, and medical care expenditures . Milbank Q 66:640-660, 1988.

12.

Hazzard WR Weight control and exercise: Cardinal features of successful preventive gerontology . JAMA 274:1964-1965, 1995 .

13.

American Heart Association. 1990 Heart and Stroke Facts. Dallas: American Heart Association, 1989, p 44.

14.

Dalessandri KM , Organ CH Surgery, drugs, lifestyle and hyperlipidemia . Am J Surg 169: 374-378, 1995.

15.

Dobkin B. The economic impact of stroke. Neurology 45(2 Suppl):S6-9, 1995.

16.

Taylor TN , Pagriciatt D. , Torner JC , et al. Lifetime cost of strokes. Stroke 27:170, 1996.

17.

Corson JD , Kresowik TF , Hoballah JJ , et al. When is lipid therapy indicated and can it be effective for patients with atherosclerotic peripheral vascular disease. In Veith FJ , ed. Current Critical Problems in Vascular Surgery, vol. 6. St. Louis: Quality Medical Publishing, 1994, pp 334-344.

18.

Miller VT Lipids, lipoproteins, women and cardiovascular disease. Atherosclerosis 108(Suppl):S73-82, 1994 .

19.

Lobo RA Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173(3Pt 2):982-989, 1995.

20.

Lew P. , Gonzalez F. , Hornung CA , et al. A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis . J Vasc Surg 23:36-45, 1996.

21.

Kwiterovich PO Jr , Coresh J. , Smity HH , et al. Comparison of the plasma levels of apolipoproteins B and A-1 and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 69:1015-1021, 1992.

22.

Valentine JR , Kaplan HS , Green R. , et al. Lipoprotein(a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: A prospective, controlled analysis. J Vasc Surg 23:53-63, 1996.

23.

Brown G. , Albers JJ , Fisher LD , et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apo-lipoprotein B. N Engl J Med 323:1289-1298, 1990 .

24.

Shepherd J. , Corbe SM , Ford I. , et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia . N Engl J Med 333:1301-1307, 1995 .

25.

Goldberg RJ , Burchfiel CM , Benfante R. , et al. Lifestyle and biological factors associated with atherosclerotic disease in middle-aged men. 20-year finding from the Honolulu Heart Program. Arch Intern Med 155:686-694, 1995.

26.

Robinson JG , Leon AS The prevention of cardiovascular disease. Emphasis on secondary prevention. Med Clin North Am 78:69-98, 1994.

27.

Frick MH , Elo O. , Happa K. , et al. Helsinki Heart Study: Primary prevention with gemfibrozil in middle aged men with dyslipemia. N Engl J Med 317:1237-1245, 1987.

28.

Law MR , Wald NJ , Thompson SG

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease?

BMJ 308:367-372, 1994.

29.

Kane JP , Mally MJ , Ports TA , et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007-3012, 1990.

30.

Chashin-Hemphill L. , Mack WJ , Pogoda JM , et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A four year follow up. JAMA 264:3013-3017, 1990 .

31.

Brensike JF , Levy RI , Kelsey SF , et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 69:313-324, 1984.

32.

Pedersen TR , Kjekshus J. , Berg K. , et al. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 334:1383-1389, 1994.

33.

Jukema JW , Bruschke AV , VanBoven AJ , et al. Effects of lipid lowering bv pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995.

34.

Pitt B. , Ellis SG , Mancini GBJ , et al. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC-1). Am J Cardiol 72:31-35, 1993.

35.

The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984.

36.

The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: Findings related to a prior hypotheses of the trial. JAMA 263:1795-1801, 1990.

37.

Kafonek S. Secondary prevention of coronary artery disease. Lipid Lett AHA 1:1-2, 1995.

38.

Siegel D. , Grady D. , Browner WS , et al. Risk factor modification after myocardial infarction. Ann Intern Med 109:213-218, 1988.

39.

Oliver MF Doubts about preventing coronary heart disease. BMJ 304:393-394, 1992.

40.

Davey Smith G , Song F. , Sheldon TA Cholesterol lowering and mortality: The importance of considering initial level of risk. BMJ 306:1367-1373, 1993.

41.

Fries JF , Koop E. , Beadle CE , et al. and the Health Project Consortium. Reducing health care costs by reducing the need and demand for medical services. N Engl J Med 329: 321-325, 1993.

42.

Hamilton VH , Racicot F. , Zowall H. , et al. The cost effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 273:1032-1038, 1995.

43.

The Writing Group of the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. JAMA 273:1429-1435, 1995 .

44.

Ornish D. , Brown SE , Scherwitz LW , et al. Can lifestyle changes reverse coronary heart disease? Lancet 336:129-133, 1990.

45.

National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89:1333-1345, 1994.

46.

Pedersen TR Lowering cholesterol with drugs and diet . N Engl J Med 333:1350-1351, 1995 .

47.

Blankenhorn DH , Hodis HN Treating serum lipid abnormalities in high-priority patients. Postgrad Med 89:81-82, 87-90, 93-96, 1991.

48.

Krupski WC Regression of atherosclerosis. Ann Vasc Surg 8:303-317, 1994.

49.

Olin JW The role of lipids in the progression and regression of atherosclerosis . In Veith FJ , ed. Current Critical Problems in Vascular Surgery, vol. 4. St. Louis: Quality Medical Publishing , 1992, pp 304-310.

50.

Blankenhorn DH , Nessim SA , Johnson RL , et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257: 3233-3240, 1987.

51.

Buchwald H. , Varco RL , Matts JP , et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med 323:946-955, 1990.

52.

Gould KL , Omish D. , Scherwitz L. , et al. Changes in myocardial perfusion abnormalities bv positron emission tomography after long-term, intense risk factor modification. JAMA 274:894-901, 1995.

53.

Furberg CD , Adams HP , Applegate WB , et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Plaque Study (ACAPS) Research Group. Circulation 90:1679-1687, 1994 .

54.

Fuster V. , Badimon JJ , Badimon L. Clinical-pathological correlations of coronary disease pregression and regression . Circulation 86(6 Suppl):III-1-III-11, 1992.

55.

DeFeyter PJ , Serruys PW , Davies MJ , et al. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis . Value, limitations and implications for clinical trials. Circulation 84:412-423, 1991.

56.

Kalra VK , Ying Y. , Deemer K. , et al. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 160:154-162, 1994.

57.

Boudoulas H. Factors determining and prevention of atherosclerotic plaque rupture. Postgrad Med J 70(Suppl 1):43-45, 1994.

58.

Badimon JJ , Fuster V. , Chesebro JH , et al. Coronary atherosclerosis. A multifactorial disease. Circulation 87(3 Suppl):113-6, 1993.

59.

Pyorala K. , DeBacker G. , Graham I. , et al. Prevention of cornary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15:1300-1301, 1994.

60.

Verschuren WMM , Jacobs DR , Bloemberg BPM , et al. Serum total cholesterol and long term coronary heart disease mortality in different cultures . JAMA 274:131-136, 1995.

61.

Lithell H. Pathogenesis and prevalence of atherosclerosis in hypertensive patients . Am J Hypertens 7(7 Pt 2):2S-6S, 1994.

62.

Iribarren C. , Reed DM , Burchfiel CM , et al. Serum total cholesterol and mortality. Confounding factors and risk modification in Japanese-American men. JAMA 273: 1927-1932, 1995 .

63.

Treasure CB , Klein L. , Weintraub WS , et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease . N Engl J Med 332:481-487, 1995.

64.

Anderson TJ , Meridity IT , Yeung AD , et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493, 1995.

65.

Atkins D. , Psaty BM , Koepsell TD , et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomised control trials. Ann Intern Med 119:136-145, 1993.

66.

Newman TB , Hulley SB Carcinogenicity of lipid-lowering drugs. JAMA 275:55-60, 1996.

67.

Welborn TA , Knuiman M. , McCann V. , et al. Clinical macrovascular disease in causasoid diabetic subjects: Logistic regression analysis of risk variables. Diabetologia 27:568-577, 1984.

68.

Beach KW , Brunzell JD , Conquest LL , et al. The correlation of arteriosclerosis obliterans with lipoproteins in insulin-dependent and non-insulin-dependent diabetes. Diabetes 28: 836-840, 1979.

69.

Brand FN , Abbott RD , Kanel WB Diabetes, intermittent claudication, and risks of cardiovascular events . The Framingham Study Diabetes 38:504-509, 1989.

70.

Rabkin WSW , Mathewson AL , Hsu PH Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26-year observation period. The Manitoba Study Am J Cardiol 39:452-458, 1977.

71.

Olsson T. , Viitanen M. , Asplund K. , et al. Prognosis after stroke in diabetic patients, a controlled prospective study. Diabetologia 33:244-249, 1990.

72.

Reaven GM Are triglycerides important as a risk factor for coronary arterv disease ? Heart Dis Stroke 2:44-48, 1993.

73.

Kannel WB Lipids, diabetes and coronary heart disease: Insights from the Framingham Study. Am Heart J 110:1100-1107, 1985 .

74.

Simpson HCR , Mann JI , Meade TW , et al. Hypertriglyceridemia and hypercoagulability . Lancet 1:786-790, 1983.

75.

Trends in smoking initiation among adolescents and young adults—United States 1980-1989. JAMA 272:528-529, 1995.

76.

Gong YL , Koplan JP , Feng W. , et al. Cigarette smoking in China: Prevalence, characteristics and attitudes in Minhand District. JAMA 274:1232-1234, 1995.

77.

Celermajer DS , Adams MR , Clarkson P. , et al. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults . N Engl J Med 334:150-154, 1996.

78.

Steenland K. Passive smoking and the risk of heart disease . JAMA 267:94-99, 1992.

79.

Hammond SK , Sorensen G. , Youngstrom R. , et al. Occupational exposure to environmental tobacco smoke. JAMA 272:956-960, 1995.

80.

Dovgan PS , Edwards JD , Zhan X. , et al. Cigarette smoking increases monocyte adherence to cultured endothelial cell monolayer. Biochem Biophys Res Commun 203:929-934, 1994.

81.

Folts JD , Geringm SA , Laibly SW , et al. Effects of cigarette smoke and nicotine on platelets and experimental coronary artery thrombosis. Adv Exp Med Biol 273:339-358, 1990.

82.

Bowlin SJ , Medalie JH , Flocke SA , et al. Epidemiology of intermittent claudication in middle aged men . Am J Epidemiol 140:418-430, 1994.

83.

Jonason T. , Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality . Acta Med Scand 221:253-260, 1986.

84.

Colditz GA , Bonita R. , Stampfer MH , et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 318:937-941, 1988.

85.

Wolf PA , D'Agostino RB , Bonita R. , Belanger AJ Cigarette smoking as a risk factor for stroke. The Framingham Study . JAMA 269:1025-1029, 1988 .

86.

Whisnant JP , Homer D. , Ingall TJ , et al. Duration of cigarette smoking is the strongest predictor of severe extracranial carotid artery atherosclerosis . Stroke 25:707-714, 1990.

87.

Krupski WC The peripheral vascular consequences of smoking. Ann Vasc Surg 5:291-304, 1991.

88.

Krumholz HM , Cohen BJ , Tsevat J. , et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 22:1697-1702, 1993 .

89.

Jorenby DE , Smith SS , Fiore MC , et al. Varying nicotine patch dose and type of smoking cessation counseling . JAMA 274:1347-1352, 1995 .

90.

Hughes JR Treatment of nicotine dependence: Is more better? JAMA 274:1390-1391, 1995.

91.

Casassus P. , Fontbonne A. , Thibult N. , et al. Upper-body fat distribution: A hyperinsulinemia-independent predictor of coronary heart disease mortality: The Paris Prospective Study Arterioscler Thromb 12:1387-1392, 1992 .

92.

Bergstrom RW , Newell-Morris LL , Leonetti DL , et al. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution in the development of NIDDM in Japanese-American men. Diabetes 39:104-111, 1990.

93.

Katzel LI , Bleecker ER , Colman EG , et al. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle aged and older men: A randomized controlled trial. JAMA 274:1915-1921, 1995.

94.

Manson JE , Colditz GA , Stampfer MJ , et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 322:882-889, 1990.

95.

Wing RR , Jeffery RW , Burton LR , et al. Change in waist-hip ratio with weight loss and its association with change in cardiovascular risk factors. Am J Clin Nutr 55:1086-1092, 1992.

96.

Ostlund RE , Staten M. , Kohrt WM , et al. The ratio of waist-to-hip circumference, plasma insulin level and glucose intolerance as independent predictors of HDL-cholesterol levels in older adults. N Engl J Med 322:229-234, 1990.

97.

Kohrt WM , Kirwan JP , Staten MA , et al. Insulin resistance in aging is related to abdominal obesity Diabetes 42:273-281, 1993.

98.

Coon PJ , Bleecker ER , Drinkwater DT , et al. Effects of body composition and exercise capacity on glucose tolerance, insulin, and lipoprotein lipids in healthy older men: A cross sectional and longitudinal intervention study. Metabolism 12:1201-1209, 1989.

99.

Manson JE , Willett WC , Stampfer MJ , et al. Body weight and mortality among women. New Engl J Med 333:677-685, 1995.

100.

Licata G. , Scaglione R. , Avellone G. , et al. Obesity, hypertension and atherosclerosis. Int Angiol 12:326-330, 1993.

101.

Baszczynski J. , Karpinski E. , Sordyl E. , et al. Epidemiology of risk factors of atherosclerosis and preventive program for youth. Int Angiol 9:20-21, 1990.

102.

Kwiterovich PO Jr. Detection and treatment of elevated blood lipids and other risk factors for coronary disease in youth. Ann N Y Acad Sci 748:313-332, 1995.

103.

Tvolano RP , Flegal KM , Kuczmavski RJ , et al. Overweight previews and trends for children and adolescents: The National Health and Nutrition Examination surveys, 1963-1991. Arch Pediatr Adolesc Med 149:1085-1093, 1995.

104.

Willet WC , Manson JE , Starpfer MJ , et al. Weight, weight change, and coronary heart disease in women. Risk within the "normal" weight range. JAMA 273:461-465, 1995.

105.

Kritz-Silverstein D. , Barett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA 275:46-49, 1996.

106.

Matthews DA , Meilahn E. , Kuller LH , et al. Menopause and risk factors for coronary heart disease. N Engl J Med 321:641-646, 1989.

107.

Paganini-Hill A. , Chao A. , Ross RK , et al. Exercise and other factors in the prevention of hip fracture: The Leisure World study. Epidemiology 1:16-25, 1991.

108.

Paganini-Hill A. The risks and benefits of estrogen replacement therapy: Leisure World (review). Int J Fertil Menopausal Stud 40(Suppl):54-62, 1995.

109.

Berlin JA , Colditz GA A meta-analysis of physical activity in the prevention of coronary heart disease . Am J Epidemiol 132:612-628, 1990.

110.

Paffenbarger RS Jr , Hyde RT , Wing AL , et al. The association of changes in physical activity level and other lifestyle characteristics with mortality among men . N Engl J Med 328:538-545, 1993.

111.

Blair S. , Kohl HW III , Barlow CE , et al. Changes in physical fitness and all-cause mortality. JAMA 273:1093-1096, 1995 .

112.

Powell KE , Thompson PD , Casperson CJ , et al. Physical activity and the incidence of coronary heart disease . Ann Rev Pub Health 8:253-287, 1987.

113.

Crespo CJ , Keteyian SJ , Heath GW , et al. Leisure time physical activity among US adults: Results from the Third National Health & Nutrition Examination Survey. Arch Intern Med 156:93-100, 1996.

114.

Lee IM , Hsieh CC , Paffenbarger RS Exercise intensity and longevity in men. The Harvard Alumni Health Study JAMA 273:1179-1184, 1995 .

115.

Siegel PZ , Brackbill RM , Frazier EL , et al. Behavior risk factor modification 1986-1990. MMWR Morb Mortal Wkly Rep 40(SS-4):1-23, 1991.

116.

Lakka TA , Salonen JT Physical activity and serum lipids: A cross sectional population study in eastern Finnish men. Am J Epidemiol 136:806-813, 1992.

117.

Helmrich SP , Ragland DR , Leung RW , et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 325:147-152, 1991.

118.

Hagberg JM Exercise, fitness and hypertension. In Bouchard C , Shepard RJ , Stephens T , et al., eds. Exercise Fitness and Health: A Consensus of Current Knowledge. Champaign, Ill.: Human Kinetics Publishers, 1990, pp 445-466.

119.

Tran ZV , Weltman A. , Glass GV , et al. The effects of exericse on blood lipids and lipoproteins: A meta-analysis of studies. Med Sci Sports Exerc 15:393-402, 1983.

120.

Meyers D. , Goldberg AP , Coon PJ , et al. Relationship of obesity and physical fitness to cardiopulmonary and metabolic function in healthy older men. J Gerontol 46:M57-M65, 1991.

121.

Priscon D. , Francalanci I. , Filippini M. , et al. Physical exercise and hemostasis. Int J Clin Lab Res 24:125-131, 1994.

122.

Stratton JR , Chandler WL , Schwartz RS , et al. Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 83: 1692-1697, 1991 .

123.

Collins R. , Peto R. , MacMahon S. , et al. Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context . Lancet 335:827-838, 1990.

124.

Reaven GM , Lithell H. , Landsberg L. Hypertension and associated metabolic abnormalities—The role of insulin resistance and the sympathoadrenal system. N Engl J Med 334: 374-381, 1996.

125.

Gleerup G. , Vind J. , Winther K. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients. Eur J Clin Invest 25(4):266-270, 1995.

126.

Liebson PR , Grandits GA , Dianzumba S. , et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygenic therapy in the treatment of mild hypertension study. Circulation 91: 698-706, 1995.

127.

Psaty BM , Heckbert SR , Koepsel TD , et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 274:620-625, 1995.

128.

Zemel PC , Sowers JR Relation between lipids and atherosclerosis: Epidemiologic evidence and clinical implications. Am J Cardiol 66:71-121, 1990.

129.

M.R.C. Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 304:405-412, 1992.

130.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 265:3255-3264, 1991.

131.

Bach R. , Jung F. , Kohsiek I. , et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. Thromb Res 74 (Suppl 1):S55-67, 1994.

132.

Harrington DP , Grassi CJ Percutaneous transluminal angioplasty . In Loscazzo J , Creager MA , Szau VJ , eds. Vascular Medicine. Boston/ Toronto /London: Little Brown , 1992, pp 715-769.

133.

Bergelson BA , Ruocco NA , Rvan TJ , et al. Lipoproteins predict restenosis after PTCA. Circulation 80:1165, 1989.

134.

Rapp JH , Qvarfbrdt P. , Krupski WC , et al. Hypercholesterolemia and early restenosis after carotid endarterectomy . Surgery 101:277-282, 1987.

135.

Shah PK , Amin J.

Low high density lipoprotein level is associated with increased restenosis after coronary angioplasty

Circulation 85:1279-1285, 1992.

136.

Desmaris RL , Sarembock IJ , Ayers CR , et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 91:1403-1409, 1995.

137.

Sahni A. , Manist AR , Voci G. , et al. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 121:1600, 1991.

138.

Ramo OJ , Juha L. , Martii S. , et al. Effects of lovastatin in prevention of restenosis after percutaneous transluminal angioplasty in lower limbs. Int J Angiol 4:173-176, 1995.

139.

Matsi PJ , Manninen HI , Laakso M. , et al. Impact of risk factors on limb salvage after angioplasty in chronic critical lower limb ischemia. A prospective trial. Angiology 45: 797-804, 1994.

140.

Dalsing MC , Cockerill E. , Deupree R. , et al. Outcome predictors in selection of balloon angioplasty or surgery for peripheral arterial occlusive disease. Veterans Administration Cooperative Study # 199. Surgery 110:636-644, 1991.

141.

Snyder SO , Gregoryu RT , Wheeler JR , et al. Composite grafts utilizing polytetrafluoroethylene-autologous tissue for lower extremity arterial reconstructions. Surgery 90:881-888, 1981.

142.

Rutherford RB , Jones DN , Bergentz SE , et al. Factors affecting the patency of infrainguinal bypass. J Vasc Surg 8:236-246, 1988.

143.

Ameli FM , Stein M. , Provan JL , et al. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 3:20-25, 1989.

144.

Wiseman S. , Kenchington G. , Dain R. , et al. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ 299:643-646, 1989.

145.

Prendville EJ , Yeager A. , O'Donnell TF , et al. Long-term results with the above knee popliteal expanded polytetrafluoroethylene graft . J Vasc Surg 11:517-524, 1990.

146.

Herring M. , Gardner A. , Glover J. Seeding human arterial prostheses with mechanically derived endothelium. The detrimental effect of smoking. J Vasc Surg 1:279-289, 1984.

147.

Gensini GG , Esente P. , Kelly A. Natural history of coronary disease in patients with and without coronary bypass graft surgery . Circulation 50(Suppl II):98-102, 1974.

148.

Campeau L. , Enjalbert M. , Lesperance J. , et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disase in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 311:1329-1332, 1984.